Keyphrases
Treatment Outcome
100%
Prostate Radiotherapy
100%
Combination Treatment
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Androgen Deprivation Therapy
100%
Docetaxel
80%
Androgen Receptor Antagonist
60%
Hazard Ratio
60%
Randomized Clinical Trial
40%
Overall Survival
40%
High Risk
40%
Low Volume
40%
Clinical Practice
20%
Chemotherapy
20%
Adverse Effects
20%
Disease Control
20%
Combination Therapy
20%
Metastatic Disease
20%
Management Strategy
20%
Prednisone
20%
Recurrent Disease
20%
Long-term Survival
20%
Appropriate Treatment
20%
Castration-resistant
20%
Survival Outcomes
20%
Combination Regimen
20%
Peace
20%
Combination of Therapies
20%
Darolutamide
20%
Enzalutamide
20%
Incurable Disease
20%
Triplet
20%
Resistant Disease
20%
Terminal Phase
20%
High Response Rate
20%
Abiraterone Acetate
20%
Low-risk Disease
20%
Treatment Intensification
20%
Low Volume Disease
20%
Triplet Therapy
20%
ARASENS
20%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Diseases
100%
Docetaxel
80%
Hazard Ratio
60%
Androgen Receptor
60%
Overall Survival
40%
Randomized Clinical Trial
40%
Recurrent Disease
20%
Metastatic Carcinoma
20%
Combination Therapy
20%
Long Term Survival
20%
Abiraterone Acetate
20%
Darolutamide
20%
Adverse Effect
20%
Prednisone
20%
Enzalutamide
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Diseases
100%
Docetaxel
80%
Androgen Receptor
60%
Randomized Clinical Trial
40%
Overall Survival
40%
Chemotherapy
20%
Enzalutamide
20%
Recurrent Disease
20%
Long Term Survival
20%
Darolutamide
20%
Abiraterone Acetate
20%
Combination Therapy
20%
Prednisone
20%
Neuroscience
Androgen
100%
Docetaxel
80%
Prostate
80%
Androgen Receptor
60%
Prednisone
20%
Vertebral Column
20%
Adverse Effect
20%
Abiraterone Acetate
20%
Enzalutamide
20%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Randomized Clinical Trial
66%
Overall Survival
66%
Long Term Survival
33%
Enzalutamide
33%
Prednisone
33%
Agricultural and Biological Sciences
Androgen
100%
Docetaxel
50%
Receptor
37%
Immatures
12%
Adverse Effects
12%
Prednisone
12%
Abiraterone
12%
Enzalutamide
12%